LYCOS RETRIEVER 
Remicade: Infections
built 627 days ago
In EXPRESS, through week 24, AEs occurred at a slightly higher incidence in the Remicade group (82%) compared with the placebo group (71%). The only clinically significant laboratory abnormalities that occurred more frequently in the Remicade group compared with placebo were elevated liver function tests. There were more serious AEs, including one fatal infection, in the Remicade group (6%) than in the placebo group (3%). AEs observed were generally consistent with those described in the prescribing information, including information regarding serious infections. Please see "Important Safety Information" below.
Source:
Since the 2004 findings linking Remicade and lymphoma, a new study published in the Journal of the American Medical Association confirms and quantifies the results of previous studies. The new research indicates that patients taking Remicade have triple the risk of developing a variety of cancers including Remicade lymphoma, breast, lung, and gastrointestinal cancer . Furthermore, the results of the new study suggest that patients are two times more likely to develop serious infections such as tuberculosis , pneumonia , and skin infections .
Source:
Serious infusion reactions have been reported with Remicade, including hives, difficulty breathing, and low blood pressure. Reactions have occurred during or after infusions. In clinical studies, some people experienced the following common side effects: respiratory infections (that may include sinus infections and sore throat), coughing, and stomach pain or mild reactions to infusion such as rash or itchy skin.
Source:
MORE ABOUT
Infections